PRN: PharmaBoardroom Releases 'Healthcare and Life Sciences Review Switzerland'

12/giu/2017 13:04:25 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

PharmaBoardroom Releases 'Healthcare and Life Sciences Review Switzerland'


LONDON, June 12, 2017 /PRNewswire/ --

PharmaBoardroom today releases its new 68-page Healthcare & Life Sciences Review Switzerland 2017.

This report offers companies, investors, policymakers, and stakeholders crucial insight into the specificities of Swiss pharmaceuticals, biotech, and healthcare, based on in-depth interviews conducted with leaders and pioneers across the value chain, from government representatives, global affiliate heads, and founders of innovative local SMEs.

In spite of high operating costs and a sometimes-byzantine regulatory environment, major MNCs are flocking to establish regional headquarters in a country frequently ranked the most innovative in the world. Complementary thriving ecosystems of biotech startups, contract research and manufacturing organizations, as well as a whole host of niche service providers has also sprung up across Switzerland, many of which are featured in the report.


Featured topics include:

  • The resonance of the 'Made in Switzerland' brand abroad
  • Swiss companies' cutting-edge digital prowess
  • Biotech IPOs and international investment
  • Regional clustering: Italian Switzerland
  • Contract research and manufacturing: Switzerland's leading pharma service industries


The report features in-depth interviews with:

  • Thomas Bohn, Greater Geneva Bern area (GGBa)
  • Daniel Schmutz, Helsana
  • Shigeo Taniuchi, Santen
  • Mads Stoustrup, Novo Nordisk
  • Gilles Pluntz, Ferring
  • Urs Lehmann, Similasan
  • Riccardo Braglia, Helsinn


"We have leading universities, world-class research institutions, a highly-qualified workforce and unrivalled skills in the precision industry derived from a tradition of watchmaking" -Thomas Bohn, Greater Geneva Bern area (GGBa)

"[Switzerland is] one of the [world's] most innovative pharmaceutical hotspots and this is exactly why it is so fundamentally important to be here" -Stefan Berg, NNE

"There are some 400 biotech companies currently operating in Switzerland at various stages of development, and within only the last couple of years, the country has witnessed a definite proliferation of startups." -Nik Alexakis, Swiss Biotech Association

"The key constellation Switzerland has to offer is the ability to access and manage the diversity and complexity of different markets" -Shigeo Taniuchi, Santen

Click here to register and download the report.

blog comments powered by Disqus è un servizio offerto da Factotum Srl